A randomised, double-blind, parallel-group, fixed-dose, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo and Paroxetine in participants with Major Depressive Disorder

Trial Profile

A randomised, double-blind, parallel-group, fixed-dose, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo and Paroxetine in participants with Major Depressive Disorder

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2012

At a glance

  • Drugs Paroxetine (Primary)
  • Indications Major depressive disorder
  • Focus Biomarker; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Jun 2012 According to the EudraCT record, this trial has prematurely ended.
    • 28 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top